17 June 2013Americas

US Supreme Court backs ‘rule-of-reason’ for pay-for-delay

A majority of the US Supreme Court has ruled that the US Federal Trade Commission (FTC) should be able to challenge so-called ‘pay-for-delay’ patent litigation settlements on antitrust grounds.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

European Commission targets alleged ‘pay-for-delay’ with pharma fines

20 June 2013 The European Commission’s competition directorate has levied fines totalling €146 million ($195 million) against originator pharmaceutical company Lundbeck and several producers of generics drugs.

Judge denies AstraZeneca’s bid to squash pay-for-delay challenge

27 September 2013 A federal judge has denied AstraZeneca’s motions to dismiss claims challenging its pay-for-delay deals with three generic pharmaceutical companies in connection to heartburn drug Nexium.

AstraZeneca and Ranbaxy win ‘pay-for-delay’ case

8 December 2014 A US court has spared drug companies AstraZeneca and Ranbaxy Laboratories a potentially hefty fine after ruling that a ‘pay-for-delay’ deal between them did not violate antitrust grounds.

More on this story

European Commission targets alleged ‘pay-for-delay’ with pharma fines

20 June 2013 The European Commission’s competition directorate has levied fines totalling €146 million ($195 million) against originator pharmaceutical company Lundbeck and several producers of generics drugs.

Judge denies AstraZeneca’s bid to squash pay-for-delay challenge

27 September 2013 A federal judge has denied AstraZeneca’s motions to dismiss claims challenging its pay-for-delay deals with three generic pharmaceutical companies in connection to heartburn drug Nexium.

AstraZeneca and Ranbaxy win ‘pay-for-delay’ case

8 December 2014 A US court has spared drug companies AstraZeneca and Ranbaxy Laboratories a potentially hefty fine after ruling that a ‘pay-for-delay’ deal between them did not violate antitrust grounds.

More on this story

European Commission targets alleged ‘pay-for-delay’ with pharma fines

20 June 2013 The European Commission’s competition directorate has levied fines totalling €146 million ($195 million) against originator pharmaceutical company Lundbeck and several producers of generics drugs.

Judge denies AstraZeneca’s bid to squash pay-for-delay challenge

27 September 2013 A federal judge has denied AstraZeneca’s motions to dismiss claims challenging its pay-for-delay deals with three generic pharmaceutical companies in connection to heartburn drug Nexium.

AstraZeneca and Ranbaxy win ‘pay-for-delay’ case

8 December 2014 A US court has spared drug companies AstraZeneca and Ranbaxy Laboratories a potentially hefty fine after ruling that a ‘pay-for-delay’ deal between them did not violate antitrust grounds.

More features

President Trump 2.0: Five major areas to watch

Startup CFO’s betrayal is a lesson in preparing for the worst

Sandoz lands reduced antitrust award of $70m

New president’s to-do list: Patent bills, non-competes, USPTO director?

Sanofi subsidiary fends off $450m trade secrets case

Regulatory expert joins White & Case

Teva faces $500m fine for antitrust breaches over MS drug

UK Budget: A missed opportunity?